Kala Pharmaceuticals

Waving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing out innovative spirit and deep commitment to advancing the treatment of eye diseases.Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its proprietary AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018 FDA approval of INVELTYS® for the treatment of inflammation and pain following ocular surgery and its lead product candidate, EYSUVIS® (KPI-121 0.25%), for the temporary relief of the signs and symptoms of dry eye disease. Kala recently reported positive Phase 3 results for EYSUVIS, which may enable a potential approval and launch by year-end 2020.